SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing community attention as an undervalued AI-infrastructure project on the Base network, with investors actively discussing its potential for a supply shock due to new staking mechanics and agent demand. While some are concerned by recent price volatility and selling pressure, the community remains largely focused on a long-term bullish thesis driven by the expansion of its autonomous agent ecosystem.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

crow with knife (CAW) is trending as the community rallies around its multichain expansion and deflationary tokenomics, often referring to themselves as a growing 'murder' of supporters. Investors are actively sharing bullish sentiment across social platforms and engagement channels, frequently highlighting the project's 'caw caw' brand identity and community-driven momentum.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

The NEOS Nasdaq 100 High Income ETF (QQQI) is seeing high community engagement as investors rotate into its monthly income strategy to capitalize on tech volatility. The active discussions focus on the fund's tax-efficient structure and the potential for long-term compounding through dividend reinvestment, with many users treating it as a core component of their wealth-building portfolios.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing a technical consolidation as the community debates whether the recent price pullback is a healthy cooling-off period or a precursor to further downside amid broader market fears over rising bond yields and geopolitical tensions. While bears point to institutional ETF outflows and macroeconomic headwinds as signs of a deepening bear market, bulls argue that sustained structural support and long-term institutional accumulation present an asymmetrical buying opportunity.

VanEck ETF Trust - VanEck Uranium Nuclear Energy ETF

VanEck Uranium Nuclear Energy ETF

The VanEck Uranium Nuclear Energy ETF is gaining significant momentum as the community links the surge in AI-driven power demand to a renewed push for nuclear energy infrastructure. Retail interest is intensifying, with active discussions focusing on federal policy support, the critical role of small modular reactors in powering data centers, and the potential for a long-term structural supply squeeze.

Toll Brothers, Inc. engages in the design, building, marketing, and arranging of financing for detached and attached homes in residential communities. It operates through the following geographical segments: North Region, Mid-Atlantic Region, South Region, Mountain Region, and Pacific Region. The North region segment includes Connecticut, Delaware, Massachusetts, Michigan, New Jersey, New York, and Pennsylvania. The Mid-Atlantic region segment consists of Georgia, Maryland, North Carolina, Tennessee, and Virginia. The South region segment includes Florida, South Carolina, and Texas. The Mountain region segment consists of Arizona, Colorado, Idaho, Nevada, and Utah. The Pacific region segment includes California, Oregon, and Washington. The company was founded by Robert I. Toll, and Bruce E. Toll in May 1967 and is headquartered in Fort Washington, PA.

Toll Brothers Inc.

Toll Brothers is currently in the spotlight as investors balance its strong luxury market positioning and resilient affluent customer base against concerns regarding high mortgage rates and softening housing demand. Community discussion is heavily focused on the company's upcoming earnings report, with traders closely analyzing margin trends and management's delivery guidance as indicators for the broader housing sector's stability.

Global X Funds - Global X Uranium ETF

Global X Uranium ETF

The URA ETF is currently a focal point for investors as the uranium sector faces a supply-demand crunch and renewed geopolitical interest in domestic nuclear energy infrastructure. Community sentiment remains split between long-term bullish convictions regarding nuclear's role in the AI data center energy boom and concerns over short-term technical volatility and institutional positioning.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is currently in focus as investors weigh a wave of M&A activity against broader market volatility driven by geopolitical tensions and shifting interest rate expectations. Community sentiment is deeply divided between long-term bulls highlighting undervalued assets and recent clinical pipeline successes versus those wary of sector-wide technical exhaustion and inflationary headwinds.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing heightened community anxiety as the token continues to struggle near multi-year lows, even as stakeholders look toward potential catalysts like a new spot ETF and broader institutional RWA tokenization trends. Traders are actively debating whether these depressed price levels represent a major long-term accumulation opportunity or a signal of deeper structural weakness in the altcoin sector.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for an oral plenary presentation at the AUA Annual Meeting featuring critical extended follow-up data for their lead prostate cancer program, CAN-2409. The community is actively discussing the drug's potential for durable clinical benefit, its comparison to blockbuster immunotherapy standards, and the high likelihood of a premium buyout given recent institutional accumulation.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, Marketbeat.com...

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company's stock after...

4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reiterated a "buy" rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday...

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings...

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase - Here's What Happened...

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's What Happened...

Research Analysts Issue Forecasts for FDMT FY2030 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of 4D Molecular Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will earn...

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Current Price	$9.15
Prev Close	$9.81
Open	$9.57
Dividend Yield	0.00%
50-Day Moving Average	$9.48
Beta	1.34
Avg. Volume	693,290.37
PE Ratio	-3.43

52-Week High	$12.34
52-Week Low	$3.37
Market Capitalization	$478.31M
EPS (Annual)	-$2.42
Price to Book	1.06
Revenue Per Employee	$434,739.80

FDMT
4D Molecular Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FDMT News

FDMT4D Molecular Therapeutics Inc